COMPLEX (INTEGRATED) TREATMENT OF CHRONIC CERVICITIS ASSOCIATED WITH PAPILLOMAVIRUS INFECTION IN REPRODUCTIVE AGE PATIENTS

A. Vergun, I. Makahonov, O. Kuzmenko-Chornovil, V. Kityk, S. Sereda, O. Vergun, I. Dats, Ya. Chulovskyi, B. Parashchuk, V. Kozub, O. Moshchynska, L. Komar, K. Semashko, B. Chulovskyi, M. Zaremba, L. Romanchak

Abstract


The article substantiates of the clinical relevance problem of HPV-associated chronic cervicitis in reproductive age women. The study used modern diagnostic methods for this disease. The article based an analysis of the literature and our own observations, we studied some methods of treatment of HPV-associated cervicitis and made a clinical comparison of the use of suppositories and proteflazide alcohol solution, combined therapy of inozine pranobex with simultaneous local ectocervix destruction (laser vaporization) as part of complex treatment and relapse prevention of this pathology in reproductive age women. The effectiveness of therapy of 80 reproductive age patients with verified chronic cervicitis against the background of high oncogenic risk papillomavirus infection and the results of complex treatment were analyzed.

Key words: Human papillomavirus infection, cervicitis, diagnosis, antiviral therapy, complex treatment.


Full Text:

PDF

References


Abdiraimova, R.B., Mambetova, M.E., Abdurasimova, Z.A. (2013). Proteflazid in the treatment of papillomavirus urogenital infections. Bulletin of SKFFA “Khabarshysy”, 1 (62), 129-131.

Bulanov, M.N. (2012). Ultrasound Gynecology: a course of lectures. Ed. 2-nd, in 2 parts. Moskva: VIDAR.

Dovlethanova, E.R., Prilepskaya, V.N. (2015). A differentiated approach to the treatment of genital disease in women associated with HPV infection. Obstetrics and Gynecology, 10, 118-124.

Epidemiology and Prevention of Vaccine-Preventable Diseases. Human Papillomavirus. The Pink Book: Course Textbook. 13th Edition. CDC. (2015).

Gayonova, V.E., Churkina, S.O., Lukianova E.S. [et al]. (2008). The clinical application of the new method of sonoelastography in gynecology. Kremlin medicine. Clinical Herald, 2, 18-23.

Gillet, E., Meys, J.F., Verstraelen, H. [et al]. (2011). Bacterial vaginosis is associated with urerine cervical human papillomavirus infection: a meta-analysis. BMC Infect Dis, 11 (10), 10-15.

Godlevskaya, N.A., Starovir, A.V. (2012). Efficacy of systemic and topical application of the drug Proteflazid in the treatment of the cervix pathology caused by papillomavirus infection. Woman's health, 3 (69), 80-83.

Hryanin, A.A., Reshetnikov, O.V. (2015). Inductors interferon in the treatment of genital herpes in women. Obstetrics and Gynecology, 7, 88-89.

Kedrova, A.G., Podietov, Yu.I., Kuznetsov, V.V. [et al]. (2006). The role of antiviral therapy in the complex treatment of patients with epithelial dysplasia and preinvasive cervical cancer. Obstetrics and Gynecology, 6, 27-30.

Klyucharyova, S.V., Lyalina, L.V., Danilov, S.I. [et al]. (2007). Modern methods of diagnosis and treatment of human papillomas to prevent their malignancy. Rus. journ. skin and venereal. Diseases, 4, 66-70.

Kokhanevich, E.V. (2009). Pathology of the cervix and uterine body: a guide for obstetrician-gynecologists, oncologists, cytologists, histologists, teachers and medical students. Moskva: Gidromaks.

Mayrand, M.H., Duarte-Franco, E., Rodrigues, I. [еt al]. Human papillomavirus DNA versus Papanicolaou screening tests cervical. (2007).

Moscicki, A.B., Ma, Y. [et al]. (2010). The role of sexual behavior and HPV persistence in predicting repeated infections with new HPV types. Cancer. Epidemiol. Biomarkers. Prev, 19 (8), 2055-2065.

Porras, C., Rodrigues, S.C., Hildeshein, A. [et al]. (2009). Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev, 18 (3), 863-865.

Prilepskaya, V.N. (2008). Pathology of the cervix and genital infections. Moskva: MEDpress-inform.

Prilepskaya, V.N., Nazarova, N.M., Mzarelua, G.M. [et al]. (2015). HPV-associated cervical disease – new in diagnostics. Obstetrics and Gynecology, 8, 20-26.

Rogovskaya, S.I., Mikheeva, I.V., Shipulina, O.Yu. [еt al]. (2012). Prevalence of Human Papillomavirus Infection in Russia (Review). Epidemiology and Vaccine Prevention, 1 (62), 25-33.

Roman, A., Munger, K. [2013]. The papillomavirus E7 proteins. Virology, 445 (1-2), 138-168.

Schwartz, T.Ya., Prilepskaya, V.P., Mynbaev, O.A. (2011). Isoprinosine in the treatment of human papillomavirus infection in gynecological practice. Moskva: HEOTAR-Media.

Sukhikh, G.T., Prilepskaya, V.N. (2008) New screening technologies in the prevention of cervical cancer. Prevention of cervical cancer: uterus look into the future: materials of the International scientific-practical conference. (2008, Moskva), 110-111.

Wang, X., Wang, H-K., Li, Y. (2014). Micro RNAs are biomarkers of oncogenic human papillomavirus infections. Proc. Natl. Acad. Sci. USA, 111 (11), 4262-4267.

WHO. Comprehensive Cervical Cancer Control: A guide to essential practice. A guide to essential practice. Second edition. WHO. (2014).

Yablons’ka, S.V., Fartushok, T.V., Vesel’s’kyi, S.P. [et al]. (2008). Disorders in lipid composition and properties of plasma membrane in epithelial cells of the placental villous chorion in chlamydial infection. Ukr. Biokhim Zh, 80 (2), 135-140. PMID:18819385.

Yehorov, O.O. (2010). Comprehensive diagnosis of pre-tumor diseases of the cervix. Female doctor, 5 (31), 37-43.

Zaporozhan, V.N., Marichereda, V.G., Dimcheva, L.I. (2014). The use of flavonoid glycosides in the therapy of papillomavirus genital infection in women. Journal of Health Sciences, 4(12), 93-104.




DOI: https://doi.org/10.26886/2414-634X.2(38)2020.6

Refbacks

  • There are currently no refbacks.